{
    "clinical_study": {
        "@rank": "3075", 
        "acronym": "CREATIVE", 
        "arm_group": [
            {
                "arm_group_label": "Clopidogrel + Aspirit", 
                "arm_group_type": "Active Comparator", 
                "description": "A  Standard antiplatelet therapy control group\uff1a Clopidogrel 75mg Qd + Aspirin 100mg Qd"
            }, 
            {
                "arm_group_label": "Clopidogrel + Aspirin", 
                "arm_group_type": "Active Comparator", 
                "description": "B  Double-dosage Clopidogrel group\uff1a Clopidogrel 150mg Qd + Aspirin 100mg Qd"
            }, 
            {
                "arm_group_label": "Clopidogrel + Aspirin + Cilostazol", 
                "arm_group_type": "Active Comparator", 
                "description": "C  triple antiplatelet therapy group\uff1a Cilostazol 100mg Bid + Aspirin 100mg Qd + Clopidogrel 75mg Qd"
            }
        ], 
        "brief_summary": {
            "textblock": "To identify the high-risk patients who might have in-stent thrombosis after PCI with\n      thromboelastography and to head-to-head compare two intensified antiplatelet therapeutic\n      strategies of double-dosage Clopidogrel and triple antiplatelet therapy with Cilostazol with\n      the standard antiplatelet therapy."
        }, 
        "brief_title": "Clopidogrel Response Evaluation and AnTi-Platelet InterVEntion in High Thrombotic Risk PCI Patients", 
        "condition": "Coronary Heart Disease", 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease", 
                "Heart Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "Study population: Age 18 - 75, male or non-pregnant female; stable or unstable angina with\n      evidence of myocardial ischemia, or patient with myocardial infarction; coronary angiography\n      reveals stenosis lesions; discovery of ADP induced platelet inhibition rate < 50% and MAADP\n      > 47mm via thromboelastography (indicating low responsiveness to Clopidogrel with high risk\n      for stent thrombosis formation); is able to understand the objective of the trial, takes\n      part voluntarily and signs the written informed consent form."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age 18 - 75, male or non-pregnant female;\n\n          2. Stable or unstable angina with evidence of myocardial ischemia, or patient with\n             myocardial infarction;\n\n          3. Coronary angiography reveals stenosis lesions;\n\n          4. Discovery of ADP induced platelet inhibition rate < 50% and MAADP >47mm via\n             thromboelastography (indicating low responsiveness to Clopidogrel with high risk for\n             stent thrombosis formation);\n\n          5. Is able to understand the objective of the trial, takes part voluntarily and signs\n             the written informed consent form.\n\n        Exclusion Criteria:\n\n          1. Those who have participated in other drug or therapy equipment clinical trials but\n             did not reach the main study endpoint time limit;\n\n          2. Symptoms of severe heart failure (NYHA Class III and above) or left ventricular\n             ejection fraction < 40% (ultrasound or left ventricle ngiography);\n\n          3. Pregnant or lactating women;\n\n          4. severely impaired renal function before surgery: serum creatinine > 2.0mg/dl;\n\n          5. Impaired liver function before surgery: Serum GPT > 120U/L;\n\n          6. Bleeding tendency, history of active peptic ulcer, history of cerebral hemorrhage or\n             cavum subarachnoidale bleeding, patients with antiplatelet agent and anticoagulant\n             treatment contraindications and hence are unable to undergo anticoagulant therapy;\n\n          7. Patients who are unable to withstand dual antiplatelet therapy due to allergy to\n             Aspirin, Clopidogrel or ticlopidine, heparin, contrast agent, paclitaxel and metals;\n\n          8. Leucocyte < 3.5 x 109; and/or platelet < 100,000/mm3 or > 750,000/mm3;\n\n          9. Patient's life expectancy is less than 12 months;\n\n         10. Patients who plan to undergo coronary artery bypass grafting or other surgery within\n             1 year;\n\n         11. Those waiting for heart transplant;\n\n         12. Patients who are deemed by the researchers to have low compliance and unable to abide\n             by the requirements and complete the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "1050", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01779401", 
            "org_study_id": "2011-4003-03"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Clopidogrel + Aspirit", 
                    "Clopidogrel + Aspirin + Cilostazol"
                ], 
                "intervention_name": "Clopidogrel 75mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Clopidogrel + Aspirin", 
                "intervention_name": "Clopidogrel 150mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Clopidogrel + Aspirit", 
                    "Clopidogrel + Aspirin", 
                    "Clopidogrel + Aspirin + Cilostazol"
                ], 
                "intervention_name": "Aspirin 100mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Clopidogrel + Aspirin + Cilostazol", 
                "intervention_name": "Cilostazol 100mg", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Aspirin", 
                "Cilostazol", 
                "Ticlopidine", 
                "Clopidogrel"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "PCI", 
            "platelet function monitoring", 
            "Thrombelastography", 
            "clopidogrel", 
            "cilostazol", 
            "in-stent thrombosis"
        ], 
        "lastchanged_date": "January 28, 2013", 
        "location": {
            "contact": {
                "email": "yangminfw@gmail.com", 
                "last_name": "Min Yang, Master", 
                "phone": "86 18610433489"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "zip": "100037"
                }, 
                "name": "Fuwai Cardiovascular Hospital"
            }, 
            "investigator": {
                "last_name": "Yida Tang, MDs", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "3", 
        "official_title": "Investigator Initiated Prospective Study to Investigate the Best Anti-platelet Treatment in High Thrombotic Risk PCI Patients.", 
        "overall_contact": {
            "email": "tangyida@gmail.com", 
            "last_name": "Yida Tang, PHD", 
            "phone": "86 113701018290"
        }, 
        "overall_official": {
            "affiliation": "Fuwai Hospital, CAMS & PUMC", 
            "last_name": "Yuejin Yang, PHD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "MACCE, including cardiac death, myocardial infarction, target vessel revascularization and cerebrovascular events", 
            "measure": "Major adverse cardiac and cerebrovascular events", 
            "safety_issue": "Yes", 
            "time_frame": "within 1.5years of patient enrolled"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01779401"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Cardiovascular Institute & Fuwai Hospital", 
            "investigator_full_name": "Yi-Da Tang", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Occurrence of stent thrombosis", 
                "measure": "Secondary endpoint", 
                "safety_issue": "Yes", 
                "time_frame": "within 1.5 years of patients enrolled"
            }, 
            {
                "description": "Major bleeding and minor bleeding", 
                "measure": "bleeding", 
                "safety_issue": "Yes", 
                "time_frame": "within 1.5 years of patients' enrolled"
            }, 
            {
                "description": "to evaluate with Seattle Angina Scale", 
                "measure": "quality  of life of patient", 
                "safety_issue": "No", 
                "time_frame": "within 1.5 years of patients' enrolled"
            }
        ], 
        "source": "Cardiovascular Institute & Fuwai Hospital", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Beijing Municipal Health Bureau", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Haemonetics Corporation", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Zhejiang Otsuka Pharmaceutical Co., Ltd.", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Cardiovascular Institute & Fuwai Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}